NLRP3 and obesity disorder: Sphingolipid, ceramide has been reported to initiate Nlrp3 inflammasome formation and activation in different pathological conditions including insulin resistance, obesity, Alzheimer's disease, cystic fibrosis and acute lung injury [6, 7].